0GP7.LMedivir AB (publ)

About

Established in 1987 and headquartered in Huddinge, Sweden, Medivir AB (publ) is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products. Its primary therapeutic area is oncology, with operations extending across Sweden and internationally. The company's marketed product, Zoviduo (also known as Xerclear), treats labial herpes. Medivir's robust pipeline features several investigational compounds: Remetinostat for MF cutaneous T-cell lymphoma and basal cell carcinoma; MIV-818 for liver cancer; MIV-711 for osteoarthritis; and Birinapant along with IGM-8444, both targeting solid tumors. Furthermore, Medivir engages in strategic collaborations, including a research partnership with SciLifeLab's Drug Discovery and Development Platform to discover antivirals for SARS-CoV-2, and has licensing agreements with Tango Therapeutics and Ubiquigent Limited for preclinical research programs, specifically Ubiquigent's USP7 program.

www.medivir.com

Key Statistics

Market Cap

204.94M

EPS

-0.66

Dividend Yield

0.00%

Beta

0.11

P/B

0.25

Return on Equity

-35.7%

Sector

Healthcare

Industry

Medical - Pharmaceuticals

CEO

Jens Lindberg

Employees

10

IPO Date

2023-06-07

Country

SE